What Does Merck (MRK) Lose From Ending Its Late Stage Lung Cancer Trial?

• Merck (NYSE:MRK) and Gilead Sciences have stopped a Phase III trial combining Trodelvy and Keytruda in non small cell lung cancer after interim data disappointed.
• The decision ends development of this specific Keytruda and Trodelvy combination in this cancer setting.
• The move affects expectations for Merck's oncology pipeline, where combination therapies with Keytruda play an important role.

Consider broadening your research to other large cap drug makers and healthcare stocks with more diversified late stage pipelines through 83 resilient stocks with low risk scores

For context, Merck remains a large, diversified drug maker within global healthcare, and the stock has been strong over multiple time frames. Shares trade at $128.58, with the price up 20.8% year to date and 64.7% over the past year, while the move over the past week has been a decline of 1.2%. Those figures frame how the market has treated recent pipeline and portfolio developments.

Beyond the headline: 5 risks and 2 things going right for Merck that every investor should see.

What actually changed for Merck with this trial decision?

The cancelled Phase III study means Merck will no longer pursue this specific Trodelvy and Keytruda combination in non small cell lung cancer. The external monitoring committee indicated the regimen was unlikely to show a clear overall survival benefit over Keytruda alone, so Merck and Gilead chose to stop the trial rather than keep investing time and capital. For Merck, this removes one potential add on lung cancer use case from the Keytruda centric oncology pipeline. It does not affect approved Keytruda indications or other ongoing combinations, including the separate Trodelvy Keytruda study in adjuvant triple negative breast cancer.

Does this change the Merck Narrative around oncology and diversification?

The Narrative for Merck is built around oncology leadership and a broader mix of future products to balance Keytruda concentration risk. Losing this lung cancer combination option is a setback for that effort but sits alongside recent positives like Health Canada’s approval of Keytruda plus enfortumab vedotin in muscle invasive bladder cancer and progress with ENFLONSIA in RSV prevention. Investors are likely to see this as a reminder that not every Keytruda combination converts to a commercial opportunity. This keeps attention on the depth and breadth of the rest of Merck’s late stage pipeline rather than any single regimen.

What should investors watch next after the Trodelvy Keytruda lung cancer miss?

The key forward markers are clinical and regulatory dates that show how Merck’s wider pipeline is progressing. On the vaccine side, a clear signpost is the U.S. FDA’s March 22, 2027 PDUFA decision for ENFLONSIA’s second season RSV use in high risk children, alongside the parallel European Medicines Agency review. In oncology, investors can track ongoing data and approvals for Keytruda combinations such as the recently approved bladder cancer regimen, as well as results from the adjuvant triple negative breast cancer Trodelvy Keytruda trial, to gauge whether other combinations can help offset this lung cancer disappointment in Merck’s revenue mix over time.

For the full picture including more risks and rewards, check out the complete Merck analysis. Alternatively, you can check out the community page for Merck to see how other investors believe this latest news will impact the company's narrative.

Do you think there's more to the story for Merck? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com